Inhibition of TGF-β pathway reverts extracellular matrix remodeling in T. cruzi-infected cardiac spheroids

Exp Cell Res. 2018 Jan 15;362(2):260-267. doi: 10.1016/j.yexcr.2017.11.026. Epub 2017 Dec 5.

Abstract

Chagasic cardiomyopathy (CC) is the main manifestation of Chagas Disease (CD). CC is a progressive dysfunctional illness, in which transforming growth factor beta (TGF-β) plays a central role in fibrogenesis and hypertrophy. In the present study, we tested in a three-dimensional (3D) model of cardiac cells culture (named cardiac spheroids), capable of mimicking the aspects of fibrosis and hypertrophy observed in CC, the role of TGF-β pathway inhibition in restoring extracellular matrix (ECM) balance disrupted by T. cruzi infection. Treatment of T. cruzi-infected cardiac spheroids with SB 431542, a selective inhibitor of TGF-β type I receptor, resulted in a reduction in the size of spheroids, which was accompanied by a decrease in parasite load and in fibronectin expression. The inhibition of TGF-β pathway also promoted an increase in the activity of matrix metalloproteinase (MMP)-2 and a decrease in tissue inhibitor of matrix metalloproteinase (TIMP)-1 expression, which may be one of the mechanisms regulating extracellular matrix remodeling. Therefore, our study provides new insights into the molecular mechanisms by which inhibition of TGF-β signaling reverts fibrosis and hypertrophy generated by T. cruzi during CC and also highlights the use of cardiac spheroids as a valuable tool for the study of fibrogenesis and anti-fibrotic compounds.

Keywords: 3D cell culture; Cardiac spheroids; Extracellular matrix; SB 431542; T. cruzi; TGF-β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / pharmacology
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / genetics
  • Cardiomyopathies / parasitology
  • Cardiomyopathies / physiopathology
  • Chagas Disease / drug therapy*
  • Chagas Disease / genetics
  • Chagas Disease / parasitology
  • Chagas Disease / physiopathology
  • Dioxoles / pharmacology
  • Extracellular Matrix / genetics
  • Fibronectins / genetics
  • Gene Expression Regulation / drug effects
  • Heart / parasitology
  • Heart / physiopathology*
  • Humans
  • Matrix Metalloproteinase 2 / genetics
  • Protein Serine-Threonine Kinases / genetics*
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptors, Transforming Growth Factor beta / genetics*
  • Spheroids, Cellular / drug effects
  • Spheroids, Cellular / pathology
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Transforming Growth Factor beta / genetics
  • Trypanosoma cruzi / drug effects
  • Trypanosoma cruzi / pathogenicity

Substances

  • 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
  • Benzamides
  • Dioxoles
  • Fibronectins
  • Receptors, Transforming Growth Factor beta
  • Tissue Inhibitor of Metalloproteinase-1
  • Transforming Growth Factor beta
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type I
  • Matrix Metalloproteinase 2